We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Donor Exosomes May Induce Immune Tolerance

By Biotechdaily staff writers
Posted on 14 Dec 2004
Researchers seeking ways to prevent the body from rejecting transplanted organs without the need for drugs have found that exosomes from donor dendritic cells are a rich source of antigens that are readily incorporated by the host's immature dendritic cells and are expressed in a fashion that promotes tolerance in the host for that donor's organs.

Investigators at the University of Pittsburgh (PA, USA) worked with a mouse model to monitor the effect of donor exosomes on the host immune system. More...
They injected dye-labeled exosomes extracted from dendritic cells of one mouse strain into the bloodstream of mice of a different strain. Antigen expression was followed using flow cytometry, confocal microscopy, and immuno-electron microscopy.

They found that the injected exosomes were rapidly internalized by one of three recipient immune system cell types: splenetic antigen-presenting dendritic cells, macrophages, and liver Kupffer cells. Of particular interest was the finding that the process of internalizing the donor exosomes did not affect maturation of the dendritic cells, and the mature dendritic cells expressed a mixture of host and donor antigens for presentation to CD4+ T cells. These findings were published in the November 15, 2004, issue of Blood.

"This finding is significant because current immunosuppression therapies used in the clinical setting are not able to efficiently prevent T cell activation via the indirect pathway. Perhaps the CD4+ T cells normally involved in this pathway would retreat from attack if they encountered a cell surface marker that is of both donor and recipient origin, such as that which we observed following the dendritic cell's internalization of the donor-derived exosomes,” said first author Dr. Adrian Morelli, a researcher in the transplantation institute at the University of Pittsburgh.



Related Links:
University of Pittsburgh

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Multi-Chamber Washer-Disinfector
WD 390
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.